Oncogene, 2014-02, Vol.33 (9), p.1093-1100
2014
Details
- Autor(en) / Beteiligte
- Titel
- CTGF is a therapeutic target for metastatic melanoma
- Ist Teil von
- Oncogene, 2014-02, Vol.33 (9), p.1093-1100
- Ort / Verlag
- England: Nature Publishing Group
- Erscheinungsjahr
- 2014
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Metastatic melanoma remains a devastating disease with a 5-year survival rate of less than five percent. Despite recent advances in targeted therapies for melanoma, only a small percentage of melanoma patients experience durable remissions. Therefore, it is critical to identify new therapies for the treatment of advanced melanoma. Here, we define connective tissue growth factor (CTGF) as a therapeutic target for metastatic melanoma. Clinically, CTGF expression correlates with tumor progression and is strongly induced by hypoxia through HIF-1 and HIF-2-dependent mechanisms. Genetic inhibition of CTGF in human melanoma cells is sufficient to significantly reduce orthotopic tumor growth, as well as metastatic tumor growth in the lung of severe combined immunodeficient (SCID) mice. Mechanistically, inhibition of CTGF decreased invasion and migration associated with reduced matrix metalloproteinase-9 expression. Most importantly, the anti-CTGF antibody, FG-3019, had a profound inhibitory effect on the progression of established metastatic melanoma. These results offer the first preclinical validation of anti-CTGF therapy for the treatment of advanced melanoma and underscore the importance of tumor hypoxia in melanoma progression.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0950-9232eISSN: 1476-5594DOI: 10.1038/onc.2013.47Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3965577
- Format
- –
- Schlagworte
- Animals, Antibodies, Monoclonal - pharmacology, Basic Helix-Loop-Helix Transcription Factors - genetics, Biomedical research, Cancer, Cancer therapies, Carcinogenesis, Care and treatment, Cell Line, Tumor, Connective tissue growth factor, Connective Tissue Growth Factor - antagonists & inhibitors, Connective Tissue Growth Factor - genetics, Connective tissues, Development and progression, Disease Progression, Gene Expression Regulation, Neoplastic - drug effects, Gene Expression Regulation, Neoplastic - genetics, Humans, Hypoxia, Hypoxia - genetics, Hypoxia-inducible factor 1, Hypoxia-Inducible Factor 1 - genetics, Immunodeficiency, Kinases, Matrix metalloproteinase, Matrix Metalloproteinase 9 - genetics, Melanoma, Melanoma - drug therapy, Melanoma - genetics, Melanoma - pathology, Metalloproteinase, Metastases, Metastasis, Mice, Mice, SCID, Oncology, Experimental, Physiological aspects, Severe combined immunodeficiency, Therapeutic applications, Therapeutic targets, Transforming growth factors, Tumors